Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Matrix Biol. 2016 Nov 29;60-61:190–205. doi: 10.1016/j.matbio.2016.11.008

Figure 7. TEV-pretreatment stimulates the pro-angiogenic capability of ASCs.

Figure 7

a) VEGF secretion of control ASCs and ASCs treated with TEVs and 968-TEVs as measured by ELISA. * p<0.05 vs. all other conditions. b) Schematic of endothelial cell invasion assay. c) Confocal micrographs of ASC/HUVEC co-cultures in 3-D microwells following immunofluorescent staining for CD31. Representative confocal slices of the HUVEC monolayer and sprouts within the bulk are shown. Scale bar = 50 μm. d) Corresponding quantification of HUVEC sprouts via image analysis. * p<0.05 vs. TEV, ASCs. e) Quantification of HUVEC sprouts in the presence of a VEGF neutralizing antibody. * p<0.05 vs. all other conditions, # p<0.05 vs. Ctrl/Control. f) Quantification of HUVEC sprouts into ASC-embedded or decellularized microwells. * p<0.05. g) Quantification of HUVEC sprouts within decellularized collagen gels in the absence and presence of a VEGF neutralizing antibody. ** p<0.01 vs. all other conditions. h) Confocal micrographs of HUVEC sprouts within decellularized microwells. Scale bar = 50 μm.

HHS Vulnerability Disclosure